MajorTricyclic antidepressants (TCA)×Class Ic antiarrhythmic
Updated · Methodology
Mechanism
Flecainide is a class IC antiarrhythmic (flecainide label, US Food and Drug Administration, FDA). According to the Spanish summary of product characteristics (SmPC), it prolongs the QT interval and widens the QRS complex by 12–20% (flecainide SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). According to the US label, it slows cardiac conduction in most patients and produces dose-related increases in the PR, QRS and QT intervals (FDA). With amitriptyline, QT prolongation and QRS widening on the electrocardiogram are common adverse reactions, and QT prolongation and arrhythmias have been reported after marketing. QT-prolonging drugs, including antiarrhythmics, can increase the likelihood of ventricular arrhythmias when taken with tricyclic antidepressants (amitriptyline SmPC, AEMPS). The Spanish flecainide SmPC, for its part, reports an increased risk of arrhythmias with tricyclic antidepressants. It also states that CYP2D6 extensively metabolises flecainide and that fluoxetine, paroxetine and other antidepressants raise its plasma concentration (AEMPS). CYP2D6 and CYP2C19 are the main enzymes that metabolise amitriptyline (amitriptyline SmPC, AEMPS). The US amitriptyline label lists flecainide among drugs that inhibit CYP2D6 and can raise tricyclic antidepressant concentrations (amitriptyline label, FDA).
Symptoms
QT prolongation and QRS widening themselves cause no symptoms and show only on an electrocardiogram (ECG). Like other antiarrhythmics, flecainide can have proarrhythmic effects, that is, a more severe arrhythmia, more frequent episodes of an existing arrhythmia or worse symptoms (flecainide summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label reports rare cases of torsade de pointes with flecainide (flecainide label, US Food and Drug Administration, FDA). With amitriptyline, palpitations and tachycardia are very common, atrioventricular block and bundle branch block are common, arrhythmia is rare and torsade de pointes is very rare. Cardiac arrhythmias and severe hypotension are likely at high doses and can also occur at normal doses in people with heart disease (amitriptyline SmPC, AEMPS). If a drug that inhibits CYP2D6 is added to a stable dose of a tricyclic antidepressant, antidepressant toxicity can develop abruptly (amitriptyline label, FDA).
Management
Avoid the combination. In the heart rhythm disorders for which flecainide is prescribed, amitriptyline is contraindicated in its own right. The contraindications section of the Spanish amitriptyline summary of product characteristics (SmPC) lists recent myocardial infarction, any degree of heart block, heart rhythm disorders and coronary insufficiency (amitriptyline SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The same SmPC lists QT-prolonging drugs, including antiarrhythmics, among combinations with tricyclic antidepressants that are not recommended (AEMPS). Flecainide prolongs QT according to its own documents (flecainide SmPC, AEMPS; flecainide label, US Food and Drug Administration, FDA). Flecainide is contraindicated in heart failure. Unless cardiac pacing is available, it is not given with second-degree or higher atrioventricular block, bundle branch block or distal block (flecainide SmPC, AEMPS). Use amitriptyline with caution together with QT-prolonging drugs, especially with significant bradycardia or decompensated heart failure. Electrolyte disturbances (low or high potassium, low magnesium) increase the risk of arrhythmia (AEMPS). Before starting flecainide, correct low or high potassium and other electrolyte disturbances, as well as severe bradycardia or marked hypotension (flecainide SmPC, AEMPS). With CYP2D6 inhibitors, either the tricyclic antidepressant or the other drug may need a lower than usual dose. When the inhibitor is withdrawn, the antidepressant dose may need to be increased. Monitoring antidepressant plasma levels is desirable with such combinations (amitriptyline label, FDA). If the PR interval reaches 0.30 seconds or the QRS complex 0.18 seconds, use caution with flecainide and consider a dose reduction (flecainide label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Flecainide acetate tablet (Amneal Pharmaceuticals of New York LLC) – Prescribing Information – CAST trial, CYP and CCB interactions (2017)– FDA Tambocor label, Boxed Warning (CAST); Drug Interactions §7; DailyMed setid ee9595d5-08a1-4529-9215-ddc3c7f929c4
- FDA: Amitriptyline hydrochloride tablets (amitriptyline) prescribing information (2026)– FDA label, Sun Pharmaceutical Industries, DailyMed setid 4e520c63-1cf6-40f6-a51c-3f9b0e181342, revised 09/2026, Contraindications, Warnings (Serotonin Syndrome) and PRECAUTIONS: Drug Interactions (Drugs Metabolized by P450 2D6)
- AEMPS: Ficha técnica: Amitriptilina, Tryptizol 25 mg comprimidos recubiertos con película (nº registro 37130), secciones 4.3, 4.4, 4.5 y 4.8 (2025)– AEMPS, CIMA, nº registro 37130, revisión 01/2025, secciones 4.3, 4.4, 4.5 y 4.8
- AEMPS: Ficha técnica: Flecainida, Apocard 100 mg (nº registro 57532), sección 4.5 (2025)– AEMPS, CIMA, nº registro 57532 (Apocard 100 mg comprimidos, Viatris Healthcare), revisión 06/2025, secciones 4.3, 4.4 y 4.5